A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "
Not Applicable
Recruiting
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000034885
- Lead Sponsor
- Japan Clinical Cancer Research Organization (JACCRO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who were regarded as inadequate for study enrollment by investigators. (2) Patients who refused to supply the tumor samples.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method